



Equality impact assessment

Medicine name: levodopa/carbidopa/entacapone (Lecigon®) 20 mg/ml 5 mg/ml 20 mg/ml intestinal gel

Submission reference number:

Indication: for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results, in patients not eligible for deep brain stimulation.

NMG date: 01/03/2023

AWMSG date: 19/04/2023

The impact of this medicine on equality has been assessed during this appraisal.

Have any potential equality issues been identified for this medicine? If so, what are they?
No equality issues were identified during scoping.
Would the availability of the medicine result in different impacts for protected groups (age, gender, gender reassignment, disability, pregnancy and maternity, marriage or civil partnership, race, religion or belief, sexual orientation)?
No.
Would it be more difficult in practice for a specific group to access the medicine, compared with other groups? If so, what are those barriers or difficulties? Are there any recommendations that AWMSG could make to remove or alleviate difficulties with access?
No.
How will any equality issues be addressed?
No equality issues were identified during scoping.
Does the medicine relate to an area with known health inequalities?
No.



AWTTC

All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

Is a full equality and health impact assessment needed?
--

No.

Actions:

- | |
|---|
| <ul style="list-style-type: none">• None. Continue unchanged as there is no identified negative impact. |
|---|

Approved by: Assessment lead

Date: 12/12/2022

Date of next review: 12/04/2023